<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494035</url>
  </required_header>
  <id_info>
    <org_study_id>TP19-0010</org_study_id>
    <nct_id>NCT04494035</nct_id>
  </id_info>
  <brief_title>AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System</brief_title>
  <acronym>AVATR</acronym>
  <official_title>AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Medcure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Medcure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate&#xD;
      data in up to ten (10) human subjects who are currently being treated with hemodialysis and&#xD;
      who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the&#xD;
      CAPERE® Thrombectomy System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the CAPERE® Thrombectomy System.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective (restoration of blood flow/palpable continuous thrill)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>To restore blood flow and a palpable continuous thrill without significant pulsatility in the treated graft.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective 1 (clear thrombus from graft)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>To clear thrombus from the graft to less than 25% residual blockage as assessed by fluoroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective 2 (adverse events occurrence rate)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>To achieve an occurrence rate of all device related, major adverse events combined of less than 5%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Arteriovenous Graft Thrombosis</condition>
  <arm_group>
    <arm_group_label>AVATR-Toronto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAPERE Thrombectomy System</intervention_name>
    <description>Arteriovenous graft thrombectomy</description>
    <arm_group_label>AVATR-Toronto</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dialysis patients who are &gt; 18 years of age&#xD;
&#xD;
          -  Dialysis patients with clinical signs, symptoms and presentation consistent with acute&#xD;
             thrombosis in their AV graft; onset of symptoms &lt; 14 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dialysis patients who are &lt; 18 years of age.&#xD;
&#xD;
          -  Grafts with aneurysmal degeneration&#xD;
&#xD;
          -  Central venous occlusion&#xD;
&#xD;
          -  Patients with infection of the vascular access&#xD;
&#xD;
          -  Patients with active cancer under current therapy, myeloproliferative syndromes,&#xD;
             hyperhomocysteinemia, and heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Patients with pulmonary embolism (PE) with hemodynamic compromise&#xD;
&#xD;
          -  Any contraindication to systemic or therapeutic doses of heparin or anticoagulants&#xD;
&#xD;
          -  Known anaphylactic reaction of radiographic contrast agents that cannot be pre-&#xD;
             treated&#xD;
&#xD;
          -  Imaging evidence or other evidence that suggests the participant is not appropriate&#xD;
             for mechanical thrombectomy intervention (e.g. recent access site creation where there&#xD;
             are concerns of leak or disruption of the suture line)&#xD;
&#xD;
          -  Female who is pregnant or nursing&#xD;
&#xD;
          -  Concurrent participation in another investigational drug or device treatment study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Mafeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey P DuMontelle</last_name>
    <phone>7149150886</phone>
    <email>jeff@vascularmedcure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Mafeld, MD</last_name>
      <email>SebastianCharles.Mafeld@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Sebastian Mafeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dheeraj Rajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

